Menu

Recent Interviews

Dirk Graszt, CEO, Clean Logistics SE

Dirk Graszt
CEO | Clean Logistics SE
Trettaustr.32, 21107 Hamburg (DE)

info@cleanlogistics.de

+49-4171-6791300

Interview Clean Logistics: Hydrogen challenge to Daimler + Co.


Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


06. July 2021 | 11:34 CET

Bayer, XPhyto Therapeutics, Pfizer: Here comes the blockbuster of the 4th wave

  • Biotechnology
Photo credits: pixabay.com

Hygiene sluices, rapid tests, disinfectants and vaccines - what was more familiar to laboratory staff or doctors a few years ago has become our daily bread since the outbreak of the pandemic. It stands to reason that the new normality would also leave its mark on the stock market. Indeed, the shares of major pharmaceutical companies have already risen. However, there are still newcomers with considerable potential. Growth companies, in particular, could benefit from the hype surrounding hygiene and health.

time to read: 2 minutes by Nico Popp
ISIN: BAYER AG NA O.N. | DE000BAY0017 , XPHYTO THERAPEUTICS | CA98421R1055 , PFIZER INC. DL-_05 | US7170811035


 

Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author


Bayer: Value - and what else?

Bayer is anything but a growth company. Nevertheless, the Leverkusen-based Company is currently regarded by many stock market experts as an exciting pick. Why? The Company is the market leader, shines with good figures and has largely shaken off the glyphosate dispute, which has been a burden for many years, at least in its share price. Added to this is a dividend that currently convinces many investors with more than a 5% dividend yield. While Bayer offers no hope of being the next multiplier, a hefty dividend is a good argument, especially for risk-averse investors.

In addition to its health care offerings, Bayer also operates in the agricultural technology sector, benefiting from rising commodity prices and the improving inflationary environment. The stock is not hot, but it is a solid one. Over a year, the stock has returned more than 20%. There is not so much fantasy in Bayer at the moment, but there is a lot of value.

XPhyto: Next-generation PCR test comes to Berlin

On the other hand, the young Canadian Company XPhyto Therapeutics, which does business in Germany and elsewhere, is more on the growth path. XPhyto has developed a method that enables PCR tests to deliver meaningful results within 20-25 minutes. After only a little more time than error-prone antigen tests, XPhyto's solution provides PCR-quality certainty. Airports or hotels, in particular, could take advantage of the offer. Given the upcoming wave of travel, XPhyto's solution could strike a nerve.

The Company signed an agreement with ten test centers at the end of June and sent the first tests to Berlin. In addition to test kits, XPhyto offers solutions to help the human body better absorb medical agents, such as patches and solutions, and is developing drugs. In addition to a neurological drug, the Canadians are also working with psychedelic agents. The stock has been on a dive for weeks. While this may not attract investors at first glance, XPhyto Therapeutics offers an exciting product mix. The PCR tests could become a bread-and-butter business in a quarter-wave, and the activities around psychoactive compounds spark the imagination. Investors can bookmark XPhyto - the list of potential catalysts for a turnaround is long.

Pfizer: What can the Corona profiteer do?

While fantasy lurks in XPhyto, Pfizer's stock is an open book: the Company is one of the largest pharmaceutical companies in the world, making a name for itself primarily with several blockbuster drugs, each of which generates more than USD 1 billion in annual sales. Pfizer also benefits from its collaboration with BioNTech on the Covid-19 vaccine. Still, the stock has not really gotten off the ground in the past year - the price tags show a yield of just 9%. In addition, there is a dividend of around 3.5% measured against the current share price. The Pfizer share will no longer be a high-flyer but can be a solid foundation in a conservative portfolio.


Nevertheless, for private investors especially, it can make sense to invest a little more speculatively in the pharmaceutical, laboratory diagnostics, and biotech sectors. While relevant returns on Pfizer and Bayer can only be achieved with large position sizes, courageous speculators can profit with small investments in XPhyto Therapeutics. The rapid PCR test with results from 20 minutes could become the blockbuster of the fourth wave. Given a market capitalization of less than EUR 100 million, the share price is likely to react more clearly to such a development than it would to a big player like Pfizer and Co.


Author

Nico Popp

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

21. October 2021 | 12:17 CET | by Stefan Feulner

Sartorius, Defence Therapeutics, QIAGEN - Still long potential

  • Biotechnology

Since the outbreak of the Corona pandemic, biotech and pharmaceutical shares have been among the top performers on the stock market. In addition to vaccine producers such as BioNTech and Pfizer, the share price of the US pharmaceutical Company Moderna also multiplied. Other winners included diagnostics companies and laboratory equipment suppliers, process technology specialists and manufacturers of biopharmaceuticals. Biopharmaceuticals promise enormous growth potential even after Corona, especially the market such as gene and cell therapies is growing dynamically at the moment.

Read

20. October 2021 | 11:04 CET | by Armin Schulz

Bayer, Sativa Wellness Group, MorphoSys - Can the pharmaceutical industry benefit from the new German government?

  • Biotechnology

The federal election is over, and the pharmaceutical industry has to adjust to the new political constellation. The industry is facing change. Digitization is an important topic. To not lose even more researchers to foreign countries, approval processes must be accelerated and bureaucracy reduced. If we always acted as decisively as we did during the pandemic, much more could be achieved. The new federal government is flirting with the legalization of cannabis. If this were to happen, the market would probably be huge. The next four years promise to be exciting.

Read

18. October 2021 | 10:44 CET | by Nico Popp

BioNTech, Cardiol Therapeutics, Bayer: Where triple-digit returns beckon

  • Biotechnology

The pandemic is drawing to a close. Vaccination rates are high, and a new wave is - fortunately - not picking up speed. But in this environment, what is happening to many highly acclaimed pandemic stocks? Are vaccine manufacturers still interesting at the moment? We look at how the industry is faring and where opportunities can still be found.

Read